Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We …

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors …

Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly
have detectable BCR-ABL kinase domain mutations. It is unclear whether patients who …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread perception
that chronic myeloid leukemia (CML) has become another chronic disease, where lifelong …

Ascertaining the impact of uncharacterized perturbations on the cell is a fundamental problem
in biology. Here, we describe how a single assay can be used to monitor hundreds of …

Identification of protein–protein interactions often provides insight into protein function, and
many cellular processes are performed by stable protein complexes. We used tandem affinity …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Transcription factors (TFs) recognize specific DNA sequences to control chromatin and
transcription, forming a complex system that guides expression of the genome. Despite keen …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …